These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37474155)

  • 1. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
    Bushmaker T; Feldmann F; Lovaglio J; Saturday G; Griffin AJ; O'Donnell KL; Strong JE; Sprecher A; Kobinger G; Geisbert TW; Marzi A; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S721-S729. PubMed ID: 37474155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 5. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
    Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
    Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.
    Marzi A; Reynolds P; Mercado-Hernandez R; Callison J; Feldmann F; Rosenke R; Thomas T; Scott DP; Hanley PW; Haddock E; Feldmann H
    EBioMedicine; 2019 Nov; 49():223-231. PubMed ID: 31631035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates.
    Marzi A; Feldmann F; O'Donnell KL; Hanley PW; Messaoudi I; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S671-S676. PubMed ID: 37290042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.
    Woolsey C; Strampe J; Fenton KA; Agans KN; Martinez J; Borisevich V; Dobias NS; Deer DJ; Geisbert JB; Cross RW; Connor JH; Geisbert TW
    J Infect Dis; 2023 Nov; 228(Suppl 7):S712-S720. PubMed ID: 37290053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Dose Treatment With Vesicular Stomatitis Virus-Based Ebola Virus Vaccine Expressing Ebola Virus-Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease.
    O'Donnell KL; Callison J; Feldmann H; Hoenen T; Marzi A
    J Infect Dis; 2023 Nov; 228(Suppl 7):S677-S681. PubMed ID: 37186162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
    Kasereka MC; Mumtaz Z; Hawkes MT
    Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.
    Geisbert TW; Daddario-DiCaprio KM; Williams KJ; Geisbert JB; Leung A; Feldmann F; Hensley LE; Feldmann H; Jones SM
    J Virol; 2008 Jun; 82(11):5664-8. PubMed ID: 18385248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine.
    Wong G
    mBio; 2019 Jul; 10(4):. PubMed ID: 31311887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
    Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
    PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
    Suder E; Furuyama W; Feldmann H; Marzi A; de Wit E
    Hum Vaccin Immunother; 2018; 14(9):2107-2113. PubMed ID: 29757706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.